Advanced in Primary Biliary Cholangitis

Dr. Sonal Kumar

Hepatology
Weill Medical College Of Cornell
525 E 68th St, 
New York, NY 
14 Years of Experience
Advanced in Primary Biliary Cholangitis
Weill Medical College Of Cornell
525 E 68th St, 
New York, NY 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Sonal Kumar is a Hepatologist in New York, New York. Dr. Kumar has been practicing medicine for over 14 years and is rated as an Advanced provider by MediFind in the treatment of Primary Biliary Cholangitis. Her top areas of expertise are Hepatitis, Jaundice, Hepatitis C, Gastric Bypass, and Endoscopy.

Her clinical research consists of co-authoring 77 peer reviewed articles and participating in 6 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article and participated in 2 clinical trials in the study of Primary Biliary Cholangitis.

Graduate Institution
Washington University School Of Medicine
Specialties
Hepatology
Licenses
Internal Medicine in MA
Hospital Affiliations
New York-Presbyterian Hospital
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
EmblemHealth
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • OTHER COMMERCIAL
  • OTHER MEDICARE PART D
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Health First
  • HMO
  • POS
Highmark
  • EPO
  • HMO
  • PPO
Horizon Healthcare
  • EPO
  • POS
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Independent Health
  • EPO
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 10 Less Insurance Carriers -

Locations

WEILL MEDICAL COLLEGE OF CORNELL
525 E 68th St, New York, NY 10065

Additional Areas of Focus

Dr. Kumar has provided the following conditions as areas of focus. Please note that we may not have enough data to validate their experience in some of these conditions.

Non-Alcoholic Fatty Liver Disease
Nonalcoholic Steatohepatitis (NASH)

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

6 Clinical Trials

A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
A Seamless, Adaptive, Phase 2b/3, Double-Blind, Randomized, Placebo-controlled, Multicenter, International Study Evaluating the Efficacy and Safety of Belapectin (GR MD-02) for the Prevention of Esophageal Varices in NASH Cirrhosis
Enrollment Status: Active_not_recruiting
Publish Date: April 11, 2025
Intervention Type: Drug
Study Drug: Belapectin
Study Phase: Phase 2/Phase 3
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Long-Term, Placebo-Controlled, Multicenter Study Evaluating the Safety and Efficacy of Obeticholic Acid in Subjects With Nonalcoholic Steatohepatitis
Enrollment Status: Terminated
Publish Date: October 01, 2024
Intervention Type: Drug
Study Drug: Obeticholic Acid
Study Phase: Phase 3
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Evaluate the Efficacy and Safety of Obeticholic Acid in Subjects With Compensated Cirrhosis Due to Nonalcoholic Steatohepatitis
Enrollment Status: Completed
Publish Date: October 23, 2023
Intervention Type: Drug
Study Drug: Obeticholic acid
Study Phase: Phase 3
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
A Phase 4, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Effect of Obeticholic Acid on Clinical Outcomes in Patients With Primary Biliary Cholangitis
Enrollment Status: Terminated
Publish Date: March 09, 2023
Intervention Type: Drug
Study Drug: Obeticholic Acid 
Study Phase: Phase 4
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
A Phase 2 Dose Ranging, Randomized, Double Blind, Placebo-Controlled Study Evaluating the Safety, Tolerability, Pharmacokinetics and Efficacy of EDP-305 in Subjects With Primary Biliary Cholangitis (PBC) With or Without an Inadequate Response to Ursodeoxycholic Acid (UDCA)
Enrollment Status: Completed
Publish Date: May 18, 2021
Intervention Type: Drug
Study Phase: Phase 2
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Oral Hepatitis C Treatment for Indolent Lymphoma (OPTImaL) Study
Enrollment Status: Terminated
Publish Date: January 08, 2019
Intervention Type: Drug
Study Phase: Phase 4
View 5 Less Clinical Trials

79 Total Publications

Managing Chemotherapy-Associated Cardiotoxicity: A Case of 5-Fluorouracil and Mitomycin-Induced Chest Pain.
Managing Chemotherapy-Associated Cardiotoxicity: A Case of 5-Fluorouracil and Mitomycin-Induced Chest Pain.
Journal: Cureus
Published: April 16, 2025
Similar Doctors
Elite in Primary Biliary Cholangitis
Dr. Joseph Odin
Hepatology
Elite in Primary Biliary Cholangitis
Dr. Joseph Odin
Hepatology

Icahn School Of Medicine At Mount Sinai

5 E 98th St, 
New York, NY 
 (1.7 miles away)
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Joseph Odin is a Hepatologist in New York, New York. Dr. Odin is rated as a Distinguished provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Primary Biliary Cholangitis, Cholangitis, Hepatitis, Endoscopy, and Liver Transplant.

Distinguished in Primary Biliary Cholangitis
Dr. Nancy Bach
Hepatology
Distinguished in Primary Biliary Cholangitis
Dr. Nancy Bach
Hepatology

Icahn School Of Medicine At Mount Sinai

1450 Madison Ave, 
New York, NY 
 (1.8 miles away)
212-241-8545
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Nancy Bach is a Hepatologist in New York, New York. Dr. Bach is rated as a Distinguished provider by MediFind in the treatment of Primary Biliary Cholangitis. Her top areas of expertise are Primary Biliary Cholangitis, Reynolds Syndrome, Hepatitis, Cirrhosis, and Liver Transplant.

Distinguished in Primary Biliary Cholangitis
Dr. Ira Jacobson
Hepatology
Distinguished in Primary Biliary Cholangitis
Dr. Ira Jacobson
Hepatology

New York University

530 1st Ave, 
New York, NY 
 (1.9 miles away)
212-263-7300
Experience:
46+ years
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Ira Jacobson is a Hepatologist in New York, New York. Dr. Jacobson has been practicing medicine for over 46 years and is rated as an Elite provider by MediFind in the treatment of Primary Biliary Cholangitis. His top areas of expertise are Hepatitis, Hepatitis C, Cirrhosis, Liver Transplant, and Endoscopy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Kumar's expertise for a condition
ConditionClose
    View All 8 Advanced Conditions
    View All 18 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile